Business Description
Camurus AB
ISIN : SE0007692850
Compare
Compare
Traded in other countries / regions
CAMX.SwedenCAMRF.USACAMXs.UK7CA.Germany IPO Date
2015-12-08Description
Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The Camurus' clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company's product pipeline includes CAM2029, CAM4072 and CAM2043.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 48.55 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | 0.04 | |||||
| Interest Coverage | 418.36 | |||||
| Piotroski F-Score | 9/9 | |||||
| Altman Z-Score | 42.66 | |||||
| Beneish M-Score | -2.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 69.3 | |||||
| 3-Year Book Growth Rate | 19.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 36.21 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.41 | |||||
| Quick Ratio | 4.13 | |||||
| Cash Ratio | 3.23 | |||||
| Days Inventory | 309.41 | |||||
| Days Sales Outstanding | 53.71 | |||||
| Days Payable | 232.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.8 | |||||
| Shareholder Yield % | -0.12 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 92.87 | |||||
| Operating Margin % | 31.07 | |||||
| Net Margin % | 25.13 | |||||
| FCF Margin % | 34.76 | |||||
| ROE % | 33.61 | |||||
| ROA % | 26.38 | |||||
| ROIC % | 58.4 | |||||
| ROC (Joel Greenblatt) % | 579.63 | |||||
| ROCE % | 41.71 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 64.75 | |||||
| Forward PE Ratio | 104.17 | |||||
| PE Ratio without NRI | 64.75 | |||||
| Price-to-Owner-Earnings | 71.03 | |||||
| PS Ratio | 16.24 | |||||
| PB Ratio | 18.07 | |||||
| Price-to-Tangible-Book | 18.34 | |||||
| Price-to-Free-Cash-Flow | 46.73 | |||||
| Price-to-Operating-Cash-Flow | 45.95 | |||||
| EV-to-EBIT | 48.03 | |||||
| EV-to-EBITDA | 46.85 | |||||
| EV-to-Revenue | 15.41 | |||||
| EV-to-FCF | 44.88 | |||||
| Price-to-Projected-FCF | 273.53 | |||||
| Price-to-Graham-Number | 7.27 | |||||
| Price-to-Net-Current-Asset-Value | 22.3 | |||||
| Price-to-Net-Cash | 34.83 | |||||
| Earnings Yield (Greenblatt) % | 2.09 | |||||
| FCF Yield % | 2.17 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers